Drugs / MVT-1075
MVT-1075
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03118349 | Jun 2017 → Apr 2018 | pancreatic adenocarcinoma | BioNTech SE | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVT-1075 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03118349 ↗ |
| Known as | 177lu-chx-a'-dtpa-humab-5b1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297790 ↗ |
| Known as | MONO-177LU-DTPA-MVT-5873 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297790 ↗ |
| Modality | Monoclonal antibody | “177Lu Human Monoclonal Antibody 5B1 (MVT-1075)” NCT03118349 ↗ |